

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

NCT06430528

Status	RECRUITING
Sponsor	University of Michigan
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (3)

- Endogenous Cushing syndrome, either following surgery or not candidates for surgery
- Under consideration to receive osilodrostat as part of their clinical care
- Able to provide informed consent.

Exclusion (2)

- Treatment with other investigational drugs within 30 days or five half-lives (whichever is longer).
- A history of hypersensitivity to osilodrostat or therapies of a similar chemical class.

Locations (1 total)

University of Michigan, Ann Arbor, Michigan, United States